Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Search by expertise, name or affiliation
SeluDex: A phase IB/II open label study of the MEK-inhibitor selumetinib in combination with dexamethasone for paediatric and adult patients with 2nd relapsed precursor B- or T-ALL
Billingham, Lucinda
(Co-Investigator)
Kearns, Pamela
(Principal Investigator)
Cancer Clinical Trials Unit
Overview
Fingerprint
Research output
(2)
Research output
Research output per year
2021
2021
2022
2022
1
Article
1
Preprint
Research output per year
Research output per year
1 results
Publication Year, Title
(descending)
Publication Year, Title
(ascending)
Title
Type
Filter
Article
Search results
2022
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial
Menne, T.
,
Slade, D.
,
Savage, J.
,
Johnson, S.
,
Irving, J.
,
Kearns, P.
,
Plummer, R.
,
Shenton, G.
,
Veal, G. J.
,
Vormoor, B.
,
Vormoor, J.
&
Billingham, L.
,
4 Mar 2022
,
In:
BMJ open.
12
,
3
,
12 p.
, e059872.
Research output
:
Contribution to journal
›
Article
›
peer-review
Open Access
File
AZD 6244
100%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
59%
Dexamethasone
55%
Pediatrics
38%
T-Lymphoid Precursor Cells
21%
64
Downloads (Pure)